Early Detection Research Network

Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection

Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection
201
Liu, Alvin Y.University of Washington
Liu, Alvin Y.University of Washington
CD90
No design specified.
Proteomics
[u'Prostate and Urologic Cancers Research Group']
2

CD90/THY1 is overexpressed by tumor-associated stromal cells as scored by immunohistochemistry, RT-PCR analysis of laser-capture microdissected cells. CD90 protein is detected by quantitative glycopeptide-capture proteomics in tissue digestion media preparations, and also by Western blotting. CD90 protein is detected in urine. The goal is to determine if urinary CD90 level can be used to detect cancer.

To develop multiple reaction monitoring (MRM) proteomics to measure CD90 in urine samples of pre-op(erative) prostate cancer, biopsy negative, post-op, pre-op bladder cancer, and non-cancer. MRM uses triple quadrupole mass spectrometer and synthetic isotopically labeled CD90 signature peptides for detection at the fmol level.
Genomic (Affymetrix GeneChip) analysis of sorted cancer cells and their normal counterpart (CD26+ prostate cancer vs. CD26+ luminal; CD90+ tumor-associated stromal vs. CD49a+ stromal; CD9+ bladder cancer vs. CD9+ superficial urothelial) to identify up-regulated genes encoding secreted or extracellular proteins. Proteomic analysis based on mass spectrometry to measure urinary levels of the protein candidates identified.
Since CD90 is expressed by many other cell types (e.g., T cells), its prostate cancer specificity as a urinary marker needs to be rigorously tested.